IL18 and diabetic kidney disease: As displayed in Figure 6A–D, EGCG treatment decreased the levels of inflammatory factors TNF‐α, IL‐6, IL‐1β, and IL‐18, as well as the gene and protein expression of TXNIP, ASC, NLRP3, caspase1, and IL‐1β compared to untreated DKD mice, which aligned with our in vitro findings.